Cytokine production in advanced head and neck cancer patients Conti-Freitas LC et al. allowing the tumor to escape from the immune system (17,18). In this study, the level of IL-10 production by non-adherent cells was similar to that of the control cells. This result indicates that the primary activity of IL-10 is not associated with the cellular response. The true role of IL-10 in the immunoregulation of cancer remains controversial (19-21). Although the influence of IFN-c levels on patient prognosis has not been examined, further studies that demonstrate the relationship between activity levels and angiogenic factors (22) and that evaluate other variables that can alter the capacity of the immune system, such as alcohol consumption, poor nutrition and smoking, may support the clinical application of BCG in selected patients. Ultimately, BCG may help modify disease progression in terms of survival and prognosis parameters. In conclusion, patients with advanced supraglottic lar- yngeal cancer exhibited an in vitro deficiency in IFN-c secretion by mononuclear cells. Stimulated cells seem to recover this function in the postoperative period. ACKNOWLEDGMENTS The authors are grateful to Maria Aparecida Nunes Ferreira for technical assistance. AUTHOR CONTRIBUTIONS Conti-Freitas LC made substantial contributions to the conception and design of the study; participated in the acquisition and interpretation of the data and was involved in the drafting of the manuscript. Foss-Freitas MC participated in the drafting of the manuscript and performed the statistical analysis. Mamede RCM participated in the study conception and design and in the data interpretation. Foss NT conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript. REFERENCES 1. Razack AH. Bacillus calmette-gue´rin and bladder cancer. Asian J Surg. 2007;30(4):302-9, http://dx.doi.org/10.1016/S1015-9584(08)60045-7. 2. Farias T, Dias FL, Sa´ GM. Brazilian trends in laryngeal cancer treatment. Rev Bras Cir Cab Pesc. 2006;35(1):16-21. 3. Chretien PB. Unique immunobiological aspects of head and neck squamous carcinoma. Can J Otolaryngol. 1975;4(2):225-35. 4. Coulie PG. Human tumors are recognized by T cells: new perspectives for anticancer vaccines? Molecular Medicine Today. 1997;3:261-8, http:// dx.doi.org/10.1016/S1357-4310(97)01049-6. 5. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 2005;175(1):5-14. CLINICS 2012;67(6):587-590 6. Conti-Freitas LC, Foss-Freitas MC, Mamede RCM, Foss NT. Effect of BCG stimulus on proinflammatory cytokine production in laryngeal cancer. Cancer Immunol Immunother. 2009;58(1):25-9, http:// dx.doi.org/10.1007/s00262-008-0520-7. 7. Foss MC, Foss NT, Paccola GMGF, Silva CL. Serum levels of tumor necrosis factor in insulin-dependent diabetic patients. Brazilian J Med Biol Res. 1992;25(3):239-42. 8. Eilber FR, Morton DL, Ketcham AS. Immunologic abnormalities in head and neck cancer. Am J Surg. 1974;128(4):534-8, http://dx.doi.org/ 10.1016/0002-9610(74)90269-4. 9. Scully C. The immunology of cancer of head and neck with particular reference to oral cancer. Oral Surg. 1982;53(2):157-69, http://dx.doi.org/ 10.1016/0030-4220(82)90282-1. 10. Katz AE. Immunobiologic staging of patients with carcinoma of head and neck. Laryngoscope. 1983;93(4):445-63. 11. Schantz SP, Liu FJ. An immunologic profile of young adults with head and neck cancer. Cancer. 1989; 64(6):1232-7, http://dx.doi.org/10.1002/ 1097-0142(19890915)64:6,1232::AID-CNCR2820640612.3.0.CO;2-U. 12. Conti-Freitas LC, Foss-Freitas MC, Mammede RCM, Foss NT. Effect of surgical treatment on lymphoproliferation in advanced supraglottic laryngeal cancer. Laryngoscope. 2007;117(2):268-72, http://dx.doi.org/ 10.1097/01.mlg.0000249956.30424.33. 13. Gallo O, Libonati GA, Gallina E, Fini-Storchi O, Giannini A, Urso C, et al. Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1991;117(9):1007-10, http://dx.doi.org/10.1001/archotol.1991.01870210079015. 14. Curfs JHAJ, Meis JFGM, Hoogkamp-Korstanje JAA. A primer on cytokines: sources, receptors, efects, and inducers. Clin Microb Rev. 1997;10(4):742-80. 15. Melinceanu L, Sarafoleanu C, Lerescu L, Tucureanu C, Caras¸ I, Sa˘la˘geanu A. Impact of smoking on the immunological profile of patients with laryngeal carcinoma. J Med Life. 2009;2(2):211-8. 16. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol. 1995;155(4):2240-7. 17. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181-273, http://dx.doi.org/10.1016/ S0065-2776(08)60911-6. 18. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An entoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72(9):3666-70, http://dx.doi.org/10.1073/ pnas.72.9.3666. 19. Kato H, Whiteside TL. Expression of IL-10 and IL-10 receptors on peripheral blood lymphocytes and monocytes in human head and neck squamous cell carcinoma. Tokai J Exp Clin Med. 2011;36(4):144-51. 20. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst. 1996;88(8):536–41. 21. Venetsanakos E, Beckman I, Bradley J, Skinner JM. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumors. Br J Cancer. 1997;75(12):1826–30, http://dx.doi.org/ 10.1038/bjc.1997.311. 22. Cintra FF, Etchebehere M, Gonc¸alves JC, Cassone AE, Amstalden EM. Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors clinical and histological correlation. Clinics. 2011;66(9):1591-6, http://dx.doi.org/10.1590/S1807-59322011000900015. 590